Seppelt PC, et al. - Researchers evaluated outcomes of surgical aortic valve replacement (SAVR), transapical (TA), and transfemoral (TF) transcatheter aortic valve replacement (TAVR) in patients with liver disease. Of 4,394 patients who underwent aortic valve replacement from January 2004 and August 2016, 85 (mean follow-up 504 ± 733 days, age 73.4 ± 9.2 years, 44.7% female) had preexisting liver disease (median model of end-stage liver disease score 11, MELD-Na). Among those, TF-TAVR was performed on 30, TA-TAVR on 13, and SAVR on 42. They found that patients with liver disease undergoing AVR had increased perioperative risks, but long-term survival following TF-TAVR vs SAVR was favorable. MELD-Na and Society of Thoracic Surgeons Predicted Risk of Mortality and Morbidity were identified as valuable predictors for baseline risk stratification in these patients.